Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Olodaterol in Hepatic Impairment
NCT02171832Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of olodaterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-normalized area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity and Dose-normalized maximum concentration of the analyte in plasma. Started Jul 2009; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02171832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171832.